Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

Status:
Terminated

Trial end date:
2008-09-01

Target enrollment:

Participant gender:

CLL dosing escalating study; daily dosing schedule; PK/PD safety

Phase 1

Biogen